A piece of news
The company has raised €100,000 to research personalized cancer treatments
Catalan biotechnology firm ZeClinics, created at Pompeu Fabra University (UPF) and established in the Barcelona Biomedical Research Park (PRBB), has closed the largest science crowdfunding campaign of 2015 in Spain, raising a total of €100,000. A total of 64 investors contributed to this sum, thus becoming partners in the company.
The funds raised will go towards a project with zebrafish to research how to replicate cancer in small fish to personalize treatment. This research will allow the company to develop their personalized-medicine system for cancer patients, called ZeOncoTest.
This system is based on transplanting a patient’s cancer into a group of fish embryos, where a wide variety of potential treatments can be tested to find the most effective therapy in each case. Moreover, with ZeOncoTest, the company aims to cut time and lower costs, as the trials of this type done so far –normally in mice- take months to yield results and are very costly.
The campaign, launched on 9 February, was carried out through Capital Cell, a crowdfunding platform specifically for health and biotechnology. With these results, the platform has funded the largest science crowdfunding actions of both 2014 and 2015 (Iproteos and ZeClinics).